APPENDIX 3: CALL FOR EVIDENCE |
The House of Lords Select Committee on Science and
Technology has appointed a Sub-Committee, chaired by Baroness
Finlay of Llandaff, to investigate allergy and allergic diseases.
The inquiry will address all types of allergy and cover a full
range of policy issues. However, the inquiry will not focus primarily
on allergy service provision, which was the subject of recent
reports by the House of Commons Health Committee and the Department
The Committee invites evidence on all aspects of
allergy, and in particular on the following questions:
Defining the problem
- What is allergy? What is the difference
between allergy and intolerance?
- What is and what is not known about the origins
and progression of allergic disease?
- Why is the incidence of allergy and allergic
diseases rising? Why does the UK in particular have such high
prevalence of allergy?
- What gaps exist in establishing the overall disease
burden for all types of allergy and what are the barriers to filling
- In addition to the impact on the health service,
what is the overall socio-economic impact of allergic diseases
(for example, absence from work and schools)?
Treatment and management
- What is the effect of current
treatments on the natural history of allergic disease?
- What is the evidence-base for pharmacological
and non-pharmacological management strategies?
- Is the level of UK research into allergy and
allergic disease adequate?
- What are the most promising areas of research
into preventing or treating allergy?
- How effective have existing Government
policy and advice been in addressing the rise in allergies?
- How is current knowledge about the causes and
management of allergic disease shared within Government? For example,
- Do housing policy and regulations governing the
indoor environment pay enough attention to allergy?
- How effectively are food policy and food labelling
regulations responding to the rise in food allergies?
Patient and consumer issues
- What impact do allergies have
on the quality of life of those experiencing allergic disease
and their families?
- What can be done to better educate the public
and to improve the quality of information that is available to
patients and undiagnosed sufferers?
- Are current regulatory arrangements, for example,
those governing private clinics offering diagnostic and therapeutic
services and the sale of over the counter allergy tests, satisfactory?
155 op cit. Health
Committee, 6th Report (2003-04): The Provision of Allergy Services
(HC 696-1) and op cit. DH A review of services for allergy. Back